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The Marburg viruses Musoke (MARV-Mus) and Angola (MARV-Ang) have highly similar genomic
sequences. Analysis of viral replication using various assays consistently identiﬁed MARV-Ang as the
faster replicating virus. Non-coding genomic regions of negative sense RNA viruses are known to play a
role in viral gene expression. A comparison of the six non-coding regions using bicistronic minigenomes
revealed that the ﬁrst two non-coding regions (NP/VP35 and VP35/VP40) differed signiﬁcantly in their
transcriptional regulation. Deletion mutation analysis of the MARV-Mus NP/VP35 region further
revealed that the MARV polymerase (L) is able to initiate production of the downstream gene without
the presence of highly conserved regulatory signals. Bicistronic minigenome assays also identiﬁed the
VP30 mRNA 50 untranslated region as an rZAP-targeted RNA motif. Overall, our studies indicate that the
high variation of MARV non-coding regions may play a signiﬁcant role in observed differences in
transcription and/or replication.
& 2013 Elsevier Inc. All rights reserved.Introduction
Ebola (EBOV) and Marburg (MARV) virus are members of the
family Filoviridae, which belongs to the order Mononegavirales.
The isolation of highly pathogenic strains of MARV (Towner et al.,
2006) now makes rates of fatality from MARV similar to those of
EBOV in Zaire, Sudan and Ivory Coast (Fields et al., 2007)—fatalities
originating from a viral-induced hemorrhagic fever that reach rates
of up to 90% (Slenczka, 1999; Towner et al., 2006).
The MARV genome, like other members of the order, is a negative
sense single stranded (NSS) RNA genome just over 19 kb in length
that encodes seven genes (Feldmann et al., 1992). Transcription is
known to initiate at the 30-terminus (leader region) of an encapsi-
dated genome with one or more stem-loop genomic RNA structures
functioning as promoter elements for RNA-dependent RNA-poly-
merase (RdRp) binding and transcriptional initiation (Enterlein et al.,
2009; Muhlberger et al., 1998, 1999; Weik et al., 2002). Upon
transcription initiation, the RdRp scans the genome for conserved
stop and start signals with viral genes expressed in a sequential
manner (Iverson and Rose, 1982; Kolakofsky et al., 2004). Filoviruses
encode four nucleocapsid proteins (NP, VP35, VP30 and L), yet EBOV
is known to require NP, VP35, VP30, and L for enhanced transcrip-
tional activity and viral replication while MARV transcription is fully
supported by NP, VP35 and L (Muhlberger et al., 1999). VP30 plays all rights reserved.
rson).more signiﬁcant role in MARV replication—since recovery of
recombinant viruses is only achieved with transient expression of
MARV VP30 (Enterlein et al., 2006).
Filovirus genomes, like other members of the order
Mononegavirales, have a conserved sequence of cis-acting genomic
elements that regulate transcription (Barr et al., 2002). Viral gene
coding sequences are ﬂanked by 50 and 30 non-coding regions (NCRs),
followed by highly conserved stop, poly (A), start signals and
intergenic regions (IGRs) of various lengths between the poly
(A) and start signals (RR); with genomic region between VP30 and
VP24 lacking an IGR due to overlapping start/stop signals. Numerous
studies have shown that the IGRs of vesicular stomatitis virus (VSV)
and respiratory syncytial virus (RSV) are mostly responsible for the
increasing attenuation of viral mRNA expression of genes furthest
from the 30-leader region (Barr et al., 1997; Harmon et al., 2001;
Hinzman et al., 2002; Kuo et al., 1996a, 1996b; Li and Pattnaik, 1999).
IGR sequence composition and length, size of the poly (A) tract, and
location of stop and start signals all play signiﬁcant roles in the
observed gradient of mRNA abundance from transcription by RdRps
on encapsidated NSS RNA genomes (Barr et al., 2002, 2008).
Recent isolation and sequence comparisons of more pathogenic
strains of MARV from the 2005 Angola MARV outbreak show that
among the DRC and Angola isolates compared, the highest areas of
genomic divergence were observed in the regions encoding GP and
L, plus all the non-coding regions (RRs) of the viral genome (Towner
et al., 2006). With the Uige, Angola MARV (MARV-Ang) isolate
having a fatality rate 60% higher than that of the ﬁrst known MARV,
MARV Musoke (MARV-Mus), there is a strong possibility that
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could alter viral transcription and replication. Here we present
further evidence that the replication rates of these two MARV
strains differ and that comparison of transcriptional regulation by
genomic RRs via a bicistronic minigenome identiﬁes two particular
RRs as having signiﬁcantly different characteristics; with one RR
studied in further detail.Results
ZEBOV, MARV-Mus, and MARV-Ang infectious virus particle
production and genome quantiﬁcation
The ﬁrst comparative approach involved completing viral replica-
tion analysis between these two MARVs. Virion and genome produc-
tion at speciﬁc points post-infection, using two different MOIs, were
quantiﬁed. Huh-7 cells were infected at MOIs of 0.01 and 5 with
ZEBOV, MARV-Mus, and MARV-Ang in three biological replicates.
Cellular supernatants were harvested at 4, 12, 24, 48, and 72 h post-
infection. Measuring infectious viral particle production via TCID50
assay demonstrated that all three viruses have similar growth
kinetics. At the MOI of 0.01, virus particle production was undetect-
able at the two earliest time points, 4 and 12 h post-infection. After
the 12 h time point, infectious virus particle production increased
consistently and similarly for all three viruses. All measured time
points, the most signiﬁcant differences between MARVs at low MOIs
were observed until the 72 h time point; although these differences in
replication between MARV strains were not statistically signiﬁcant
(p-value¼0.11) when measured by TCID50 assays (Fig. 1C).
The higher MOI of 5 produced very similar results in that MARV-
Ang produced a greater number of infectious virions than MARV-MusFig. 1. Filovirus replication analysis via TCID50 and RT-qPCR assays. (A and B) Huh-7
MARV-Ang (open circles) in three biological replicates at the MOIs of 0.01 and 5. qRT
indicated time points with 5% of the isolated RNA for each sample loaded in each qRT
with the standard deviation shown in vertical bars. (C and D) TCID50 assays were carrie
replicates) to measure infectious virus particle production throughout the course of
MARV-Ang using a Student’s t-test (p-valueo0.05).at the later time points. However, when using a higher MOI, ZEBOV
consistently had the greatest quantity of infectious viral particles at
the later time points, even though all three viruses had similar
measurements at or before 24 h post-infection. A Student’s t-test
statistical analysis shows a signiﬁcant difference between MARV-Mus
and MARV-Ang viral titers at 72 h post-infection (p-valueo0.05)
(Fig. 1D). Experiments with MARVs analyzed by IFA also demonstrate
a discernible difference in the levels of MARV NC formation between
the two viruses (Fig. 4). To assess the potential bias in TCID50 assays
originating from possible differences in CPE of these two MARV
strains, experiments were repeated at the high MOI conditions and
viral titers quantiﬁed at 24 h post-infection using FFU assays (Mitchell
et al., 2010). Again, differences in titers favored MARV-Ang and a
Student’s t-test of the FFU/ml produced a lower p-value of 0.07
(Supplemental Fig. S1A) when compared to the TCID50 p-value at the
same time point (0.16).
Supernatants used for quantifying infectious virus particles were
also used to isolate viral RNA for genome quantiﬁcation. In general,
ﬁlovirus genome quantiﬁcation from cellular supernatants yielded
results mirroring those for infectious virus quantiﬁcation in that
ZEBOV; MARV-Ang consistently produced a greater number of viral
genomes at time points Z24 h post-infection at both MOIs.
Amongst the MARV strains, signiﬁcant differences between quanti-
ﬁed MARV genomes were observed at the 24, 48, and 72 h time
points at the lower MOI and 12, 24, 48, and 72 h time points at the
higher MOI (p-valueo0.05) (Fig. 1A and B).
MARV-Mus and MARV-Ang mRNA and protein production
Filovirus infectious viral particle and genome quantiﬁcation
assays indicated that of the two MARVs under comparison,
MARV-Ang’s capacity for replication in Huh-7 cells was greater.cells were infected with ZEBOV (open squares), MARV-Mus (open triangles), and
-PCR was conducted with viral RNA isolated from supernatants collected at the
-PCR reaction. Each data point represents genome counts determined in triplicate
d for both MOIs (0.01 and 5) at the indicated time points (with all three biological
infection. n indicates statistically signiﬁcant differences between MARV-Mus and
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MARV protein production under similar conditions to that of viral
replication experiments were conducted. Antibodies cross-reactiveFig. 2. MARV-Mus and MARV-Ang western blot analysis. Huh-7 and Vero E6 cells were
were collected at 8, 16, 24, 48, and 72 h post-infection. Total protein concentrations w
volumes loaded for SDS-PAGE. MARV proteins were detected in western blot analysis b
and bands quantiﬁed from visualized chemiluminescent signals by ImageQuant softw
western blots as protein loading controls. Bar graphs (with error bars) show average b
each MARV protein are representative of experimental results. n indicates statisticallyto the NP, VP35, GP, and VP30 viral proteins of both MARV strains
were evaluated via western blots on puriﬁed viral particles
(Supplemental Figs. S2 and S3). Overall, western blot data showedinfected with MARV-Mus or MARV-Ang at the indicated MOI of 0.01. Cell lysates
ere determined by EZ-Quant assay, samples standardized to 100 ng/ml and equal
y anti-MARV NP, anti-MARV VP35, anti-MARV GP, and anti-MARV VP30 antibodies
are. M indicates non-infected samples (Mock). Anti-actin antibodies were used in
and signal intensities for three experimental repeats. Visualized western blots for
signiﬁcant differences using a Student’s t-test (p-valueo0.05).
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greater for MARV-Ang; with signiﬁcant differences observed for
GP and VP30 proteins (p-valueo0.05) at the MOI of 0.01
(Figs. 2 and 3). Although levels of the MARV GP and VP30 proteinsFig. 3. MARV-Mus and MARV-Ang western blot analysis. Huh-7 and Vero E6 cells were
collected 1, 3, 6, 8, 16, and 24 h post-infection. Total protein concentrations were dete
loaded for SDS-PAGE. MARV proteins were detected in western blot analysis by anti-MA
quantiﬁed from visualized chemiluminescent signals by ImageQuant software.M indica
as protein loading controls. Bar graphs (with error bars) show average band signal in
protein are representative of experimental results.were observed at the higher MOI to be higher in MARV-Ang-
infected cells, no signiﬁcant differences in the relative levels of
these MARV proteins were determined (Fig. 3). Interestingly,
experiments with MARVs and stable isotope labeling with aminoinfected with MARV-Mus or MARV-Ang at the indicated MOI of 5. Cell lysates were
rmined by EZ-Quant assay, samples standardized to 100 ng/ml and equal volumes
RV NP, anti-MARV VP35, anti-MARV GP, and anti-MARV VP30 antibodies and bands
tes non-infected samples (Mock). Anti-actin antibodies were used in western blots
tensities for three experimental repeats. Visualized western blots for each MARV
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levels of VP40, GP, VP30, and L were observed in MARV-Ang-
infected cells when compared to MARV-Mus-infected samples
(Supplemental Table 1).
To further assess and compare the transcriptional capacities of
these two MARV strains, poly(A) mRNA was isolated from MARV-
infected Huh-7 cells and analyzed by qRT-PCR using MARV NP,
VP35, GP, and VP30 gene speciﬁc primers. qRT-PCR analysis in
conjunction with comparative statistical analysis via Student’s
t-test strongly supported the western blot data at the low MOI
experimental conditions. Signiﬁcant differences in the fold change
of viral mRNAs were determined for NP at 16, 24, 48 and 72 h,
8 and 48 h for VP35 mRNA, 16 and 48 h for GP mRNA, and 8 and
48 h for VP30 mRNA (p-valueo0.05) (Fig. 5); all indicating higher
levels of these viral mRNAs for MARV-Ang. Conducting similar
qRT-PCR and statistical analysis for MARV mRNAs at the higher
MOI show that signiﬁcant differences in viral mRNAs were
observed for each of the mRNA species. MARV-Ang NP, GP, and
VP30 mRNAs were signiﬁcantly greater than MARV-Mus mRNAs at
the 16 and 1 h time points, respectively (Fig. 5). Other signiﬁcantFig. 4. MARVs IFA analysis. Huh-7 and Vero E6 cells were infected with MARV-Mus or
point post-infection. Relative MARV levels were determined for each time point by pr
antibodies. Primary antibodies were visualized via anti-monkey TxRed and anti-rabbit A
Images are a representative result of multiple time course experiments.differences in viral mRNAs favored MARV-Mus, particularly VP35
and GP mRNAs at 6 h post-infection. Data indicate that the rate of
transcription for these MARV strains differ and these differences
are consistently observed at the lower MOI in both immunoblot
and qRT-PCR experiments.
Bicistronic MARV minigenomes
Numerous studies provide evidence that non-protein coding
regions regulate gene expression in a variety of RNA viruses (Barr
et al., 1997; Harmon et al., 2001; Kolakofsky et al., 2004; Neumann
et al., 2009; Weik et al., 2002). Western blot, SILAC, and qRT-PCR data
indicate a progressing differentiation of MARV mRNA and protein
levels of MARV genes encoded furthest downstream from the
genome. A testable hypothesis is that these same types of regions
of the MARV genome have varying levels of regulatory effects during
transcription for these MARV strains. The MARV minigenome system
(3M–5M) provides an established method by which these highly
variable regions could be individually tested and compared for their
transcriptional regulatory effects. The 3M–5M system was altered toMARV-Ang at the indicated MOI, then ﬁxed with 10% formalin at the stated time
obing permeabilized cells with monkey anti-MARV NP and rabbit anti-MARV NC
lex 488 conjugated antibodies. Cellular nuclei were speciﬁcally stained with DAPI.
Fig. 5. MARV mRNA fold change determination. Huh-7 cells were infected with MARV-Mus or MARV-Ang at the indicated MOI. Fold change values for each respective
MARV mRNA (NP, VP35, GP, VP30) were determined by DDCt-fold change calculations using GAPDH mRNA levels for normalization. Bar graphs depict the log10 of the
fold-change values (y-axis) at each time point post-infection (x-axis). Gray bars correspond to MARV-Mus infected samples and black bars to MARV-Ang infected cells. Bar
graphs visualize the mean of three experimental repeats with standard deviations shown in the corresponding error bars. n indicates statistically signiﬁcant differences
using a Student’s t-test (p-valueo0.05).
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Gaussian luciferase (GLuc), separated by one of six regulatory regions
(RRs) from each MARV strain—providing a total of 12 unique
constructs (Fig. 6). Cloned RRs include nucleotide sequencesFig. 6. 3M–5M minigenomes. The 3M–5M minigenome was modiﬁed to encode two lu
separated by one of 6 MARV-Mus or MARV-Ang RRs. Negative sense, single stranded m
50-ends produced from HDV ribozyme cleavage.
Fig. 7. MARV minigenome reporter assays. HeLa cells were infected with MVA-T7, transf
the vector expressing Fireﬂy luciferase under the control of the CMV promoter, and tr
described (3). 72 h post-transfection, cellular supernatants were assayed for reporter g
function as a negative control. (A) and (B) show CLuc and GLuc RLU before normalization
Error bars show standard deviations from six independent experiments. n indicates statimmediately adjacent to the stop codon of the upstream gene and
continue to the nucleotide before the start codon of the downstream
gene. All constructs are identiﬁed by their respective adjacent genes:
NP/VP35, VP35/VP40, VP40/GP, GP/VP30, VP30/VP24, and VP24/L.ciferase reporter proteins, Cypridina luciferase (CLuc) and Guassia luciferase (GLuc),
inigenome RNA were produced in vitro via the T7 RNA promoter and appropriate
ected with the pTM1 plasmids harboring cDNAs of the MARV NP, VP35, and L genes,
ansfected with minigenome RNA from the various MARV constructs as previously
ene activity. (-)L samples transiently express only the NP and VP35 proteins and
. (C) and (D) show CLuc and GLuc RLU normalized to Fireﬂly luciferase RLU (Ratio).
istically signiﬁcant differences using a Student’s t-test (p-valueo0.05).
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bicistronic minigenome RNA demonstrate a highly complex regula-
tory pattern that is consistent across both strains, with luciferase
expression shown to be driven directly by the presence of the RdRp L
(Fig. 7). Raw RLU from CLuc and GLuc assays clearly show high levels
of luciferase activity for MARV-Ang constructs, speciﬁcally, CLuc
activity for the NP/VP35, VP35/VP40, and VP40/GP minigenomes.
Similar differences resulted when testing GLuc levels for the NP/
VP35 and VP40/GPMARV-Ang RRs (Fig. 7A and B). Normalizing CLuc
and GLuc RLU values to CMV-promoter driven ﬁreﬂy luciferase
activity shows MARV-Ang RRs producing signiﬁcantly (p-
valueo0.05) greater CLuc and GLuc measures for the NP/VP35
and VP40/GP bicistronic mini-genomes (Fig. 7C and D). Calculating a
GLuc/ CLuc RLU ratio at 72 h post-transfection, provided consistentFig. 8. MARV minigenome reporter ratios. GLuc and CLuc RLU levels were assayed
from each minigenome experiment by dividing GLuc RLU levels by CLuc RLU
levels. RLU ratios from each experimental replicate (n¼9) were averaged and
standard deviations shown in corresponding error bars. (A) Reporter assay results
in HeLa cells transiently expressing NP, VP35, and L. (B) Reporter assays calculated
in MARV-Mus infected cells transfected with 3M–5M minigenome RNA. Mini-
genome results corresponding to MARV-Mus regulatory regions are in gray bars
and MARV-Ang speciﬁc values are represented in black bars. n indicates statisti-
cally signiﬁcant differences using a Student’s t-test (p-valueo0.05).and signiﬁcant evidence that the NP/ VP35 and VP35/ VP40 RRs
from these MARV strains vary in their regulation of transcription
(p-valueo0.05) (Fig. 8A). Furthermore, similar experiments with
bicistronic minigenomes and MARV-Mus super infection provided
supporting evidence in that the MARV RRs NP/VP35 and VP35/VP40
also produced signiﬁcant differences in RLU ratios (p-valueo0.05)
(Fig. 8B). Under both experimental conditions, the NP/VP35 MARV-
Ang minigenome produced signiﬁcantly higher levels of GLuc
activity when compared to corresponding MARV-Mus construct.
Conversely, the VP35/VP40 MARV-Mus bicistronic minigenome had
a signiﬁcantly higher GLuc/ CLuc RLU ratio when compared to the
MARV-Ang counterpart.
Provided that these MARV minigenome constructs are testing the
effects on MARV genome non-coding regions and that the antiviral
protein ZAP has known activity against ﬁlovirus-encoded RNA
secondary structures (Muller et al., 2007), it was of interest to
determine whether these MARV RRs were ZAP targets since its
antiviral activity would affect observed results under these experi-
mental conditions. Expressing increasing amounts of the plasmid
pCDNA-TO-myc-rZAP in HeLa cells subsequently transfected withFig. 9. rZAP and MARV bicistronic minigenomes. HeLa cells were transfected with
increasing amounts of a plasmid expressing the recombinant protein rZAP or eGFP.
24 h later, cells were then infected with MVA-T7, transfected with plasmids pTM1-
NP, VP35, and L and minigenome RNA from MARV-Mus (A) or MARV-Ang
(B) speciﬁc bicistronic constructs. 72 h post-RNA transfection, cellular supernatants
were assayed for reporter gene activity. GLuc and CLuc RLU levels were assayed
from each minigenome experiment by dividing GLuc RLU levels by CLuc RLU levels.
Error bars show standard deviations from nine independent experiments.
n indicates statistically signiﬁcant differences using a Student’s t-test (p-valueo0.05).
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bicistronic constructs clearly shows that in both MARV strains the
MARV RR GP/ VP30 is a target of the antiviral protein rZAP (Fig. 9A
and B). The rZAP decreased GLuc/ CLuc RLU ratios by an average of
20% (50 ng rZAP), 27% (100 ng), and 29% (200 ng) in both sets of
constructs; thus identifying the VP30 mRNA 50 UTR as containing
RNA motifs recognized by rZAP. It also shows modest antiviral
activity against the MARV-Ang RR VP35/VP40. GLuc/CLuc ratios show
consistent increases of 11% (50 ng), 32% (100 ng), and 39% (200 ng),
identifying the VP35 mRNA 30 UTR of MARV-Ang as an additional
rZAP target (Fig. 9B).
MARV NP/ VP35 RR minigenome mutants
Given the observed differences between the NP/ VP35 RRs, further
analysis of these genomic sequences was pursued via deletion
mutants. Deletion constructs for each RR were generated by PCR
with each subsequent mutant missing a 200 bp region beginning at
the MARV genome position 2193. A schematic of these constructs is
shown (Fig. 10A) with the non-mutated forms identiﬁed as wild type
(WT) and deletion mutants named D-1 to D-4. Reporter assays were
conducted as described and reporter levels measured at 72 h post-
transfection, with non-normalized RLU values shown in Fig. S4.
Mutant experiments demonstrate that removing the MARV-Mus RRFig. 10. 3M–5M-NP/VP35 minigenome mutants. (A) Schematic of the 3M–5M-NP/VP35
type (WT) RRs encode the MARV genomic regions corresponding to the nucleotides
deleting 200 bp from the NP/VP35 RRs 30-end via PCR. (B) GLuc/ CLuc RLU ratios and
expressing NP, VP35, and L. Minigenome results corresponding to MARV-Mus regula
black bars.region 2193–2793 (D-1 to D-3) had no signiﬁcant effect on RLU
Ratios when compared to WT, with D-2 showing a slight decrease in
the RLU ratio (Fig. 8B). MARV-Ang D-1 to D-2 mutants show a similar
pattern when compared to the WT minigenomes; with the D-3
deletion the mutant was observed to have a 0.14 RLU Ratio decrease
of 37% when compared to WT MARV-Ang. Interestingly, removing
nucleotides 2193–2867, which include known RNA-dependent RNA
polymerase stop signal, poly A and start signal sequences, mutantD-4
produced an RLU ratio comparable to that of D-3 for the MARV-Mus
constructs, with transcriptional activity being comparable to WT
MARV-Mus NP/VP35 RR levels. The MARV-Ang NP/VP35 D-4 mutant
produced a more expected result, generating miniscule levels of GLuc
reporter activity and thus producing an RLU ratio 0.369 lower (99%
decrease) than WT. Minigenome assays were conducted without
transient expression of MARV VP30—mostly due to its suppression of
transcriptional activity. Overall, co-expression of VP30 with NP, VP35,
and L in minigenome assays with the D-1 to D-4 generated similar
results to those observed without VP30 (data not shown).Discussion
The emergence and isolation of a more pathogenic strain of
MARV in Uige, Angola, provides an ideal opportunity to systematicallymutant minigenomes for RRs corresponding to the MARV-Mus or MARV-Ang. Wild
2193–2945. Subsequent mutants (D-1 to D-4) were constructed by sequentially
standard deviations from experiments (n¼6) conducted in HeLa cells transiently
tory regions are in gray bars and MARV-Ang speciﬁc values are represented in
J.A. Alonso, J.L. Patterson / Virology 440 (2013) 51–6360determine genetic elements directly responsible for its increased
lethality. Infection of a nonhuman primate provides evidence that
MARV-Ang produced fatal disease within 8 days after inoculation
and is perceived to be more pathogenic than MARV-Mus
(Daddario-DiCaprio et al., 2006a, 2006b; Geisbert et al., 2007).
Matsuno et al. (2010) also determined that a single amino acid
mutation at position 567 in MARV-Ang GP confers increased
infectivity in C-type lectin-expressing cells and differing cathe-
psin proteolytic processing when compared to the MARV-Mus GP.
Few studies have undertaken a comparative analysis of the
known MARV strains and therefore little is known of what other
underlying mechanisms may lead to increased pathogenicity.
Initial sequence analysis of the MARV-Ang isolates shows that the
non-coding regions (Leader, Trailer, and RRs) along with GP and L
coding sequences are increasingly dissimilar (Towner et al., 2006).
Viral replication studies via TCID50 and genome quantiﬁcation
indicate MARV-Ang as having an increased replication capacity
(Fig. 1). Western blot data conﬁrmed these ﬁndings; it was further
observed that genes expressed furthest from the 30-Leader region had
the greatest difference in overall expression of protein and mRNAs
(Figs. 2–4). Mutations in the nucleocapsid proteins (NP, VP35, VP30,
and L) along with alterations of the NCRs could likely contribute to
diminished or increased transcriptional levels. Modifying the MARV
minigenome to a bicistronic system allowed for an overall compara-
tive survey of the six RRs (NP/VP35, VP35/VP40, VP40/GP, GP/VP30,
VP30/VP24, and VP24/L). An important limitation of conducting
transcriptional activity experiments and measuring (only) luciferase
activity is that not all observed differences in luciferase levels can be
directly attributed to RNA polymerase processing along the genome.
It is unknown, for instance, how the grafted MARV 30 and 50 UTRs
affect mRNA stability of the luciferase genes. Experiments with
transiently expressed NP, VP35, and L and MARV-Mus infected cells
did demonstrate the MARV-Ang NP/VP35 RR as having a 2.2-fold
greater RLU Ratio (GLuc/ CLuc) than its MARV-Mus counterpart
(Fig. 8). These results indicate that elements within MARV-Ang NP/
VP35 RR allow for enhanced production of the second reporter gene
within the minigenome context. Provided that the RdRps of Mono-
negavirales initiate transcription at the 30-Leader via binding a stable
stem-loop RNA secondary structure (Enterlein et al., 2009; Fearns
et al., 2002; Kolakofsky et al., 2004), having a cis-element that allows
the RdRp to more efﬁciently scan for downstream transcriptional
signals may provide an improved transcription and/or replication
advantage. Secondary RNA structures present in both RRs could be
potential targets for the antiviral protein ZAP (Chen et al., 2012; Gao
et al., 2002; Guo et al., 2007). ZAP, an IRF3-induced, (GSK3-beta)-
modulated protein is upregulated in the presence of viral double-
stranded RNA and shows speciﬁc activity toward ﬁlovirus RNAs
(Muller et al., 2007; Sun et al., 2012; Wang et al., 2010). Transient
expression of rZAP (the rat analog of ZAP) and MARV bicistronic
minigenomes identiﬁed the VP30 mRNA 50UTR as a major ZAP target,
while other UTRs went mostly unrecognized by its antiviral activity.
With rZAP having similar activity against both MARV VP30 mRNA
50UTRs, ZAP activity does not seem to contribute to observed
differences in viral replication and transcriptional activities.
Interestingly, the NP/VP35 RRs of MARV-Ang and MARV-Mus
have identical stop, poly (A), IGR, and start sequences; the majority
of the mutations located within the 30UTR of the NP mRNA. Deletion
mutants (D-1 to D-4), which sequentially removed 200 bp of the
30UTR of the NP gene may provide clues into potential roles of these
genomic regions. Deleting nt 2163–2763 from the MARV-Mus NP/
VP35 RR did not signiﬁcantly alter RLU ratios compared to wild-type
constructs (Fig. 10). Deletion construct of MARV-Ang had a similar
effect, again not signiﬁcantly altering reporter RLU ratios upon
sequential deletion of RR genomic sequences.
Interestingly, removing the stop, poly (A), IGR, and start signals
from the MARV-Mus NP/VP35 RR produced the unexpectedresults of continued production of the GLuc reporter (Fig. 10).
Sequence analysis of nt 2867–2945 did not reveal the presence of
an alternate consensus start signal for MARVs within these
region; however, RNA secondary structure modeling via mFold
predicts the formation of two stem-loop structures similar to
those found in the MARV leader (data not shown). Previous work
with EBOV bicistronic minigenomes demonstrates that placement
of the stable 30-leader stem-loop structure at the 50-end of the
second RNA allowed for VP30-independent transcription initia-
tion (Weik et al., 2002). Although structural models of VSV
and RSV encapsidated RNA demonstrate the formation of RNA
secondary structures within nucleoprotein-bound RNA to be
unlikely (Green et al., 2006; Tawar et al., 2009), recent studies
have shown that encapsidated RNA is RNase accessible under
certain conditions (Green et al., 2011). Overall, these results imply
that the mutations found in some of the MARV-Ang RRs enhance
expression of downstream genes, which in turn may contribute to
the increased replication capacity of the MARV-Ang isolateConclusions
Quantiﬁcation analysis by qRT-PCR of MARV genomes released
from infected Huh-7 cells strongly indicated that MARV-Ang
produced a signiﬁcantly greater number of virions at low and high
multiplicity of infection when compared to MARV-Mus. Compara-
tive analysis of viral protein production and mRNA expression by
western blot and D DCt-fold change data further supported these
observations. Experiments with bicistronic minigenomes show
that the regulatory activity of the non-coding regions NP/ VP35
and VP35/ VP40 differ signiﬁcantly between MARV-Ang and
MARV-Mus. Although the direct effects on virion production by
these RRs are best determined using recombinant MARV systems,
these data provide initial evidence that sequence variation in RRs
likely effect ﬁlovirus transcription and/or replication.Quantitative reverse transcription—PCR analysis.(i) mRNA quantiﬁcation. To quantify MARV RNA, MARV
poly(A) RNA, and GAPDH RNA the One-Step RT-PCR kit with
SYBR Green (Bio-Rad) was used in combination with primers
corresponding to the appropriate gene. The following primers
were used for each respective MARV gene: MARV NP:
50-TACTTGCGTGATGCGGGTTA-30and 50-TCCTCCCCCTCTGA-
GATTCA-30, MARV VP35: 50-CCATGAAATTGAGCGGCAAT-30
and 50-CTGGTGCAGTGGTTCTTCCA-30, MARV GP: 50-CCTCC-
TACCAACATCCGTGACT-30 and 50-CCTGTGCATGAGGGTTTT-
GA-30, MARV VP30: 50-GAGACATCACTTCGTGCAGCAT-30 and
50-TGTAATTCTGTCATGGTGTTGATCA-30. GAPDH RNA was
ampliﬁed using the following set of primers: 50-GCACCGT-
CAAGGCTGAGAAC-30 and 50-GCCTTCTCCATGGTGGTGAA-30.
Fold change levels for each respective MARV RNA were
calculated by using the DDCt equation, with GAPDH Ct values
functioning as the internal control for expression level nor-
malization. For all quantiﬁed samples, GAPDH Ct values were
determined along with the Ct values for each MARV RNA (NP,
VP35, GP, and VP30).(ii) Filovirus genome quantiﬁcation. To quantify ﬁlovirus EBOVZ and
MARV negative sense, single-stranded [()ss] genomes, a qRT-
PCR assay was developed by designing primers that amplify a
segment of the EBOVZ Trailer (nucleotide positions 18,840–
18,911) and MARV intergenic region (IR) (nucleotide positions
8,718–8,827) genomes. First, the EBOVZ Trailer and MARV IR
were cloned via RT-PCR from puriﬁed virus stock RNA, then the
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pGEM-T Easy vector (Promega) for in vitro transcription with
the MAXIscript T7 Kit (Ambion). Transcript production was
veriﬁed by electrophoresis on 1.5% agarose gels and serially
diluted in known quantities to produce standard curves using
the One-Step RT-PCR Kit with SYBR Green (Bio-Rad). After
standard curves were produced, the molecular weight for each
in vitro transcript was calculated and used to correlate genome
counts for experimental samples; at a ratio of 1:1—one EBOVZ
Trailer or MARV IR transcript is assumed to equal one complete
()ss ﬁlovirus genome. For experimental samples, 5% of the
supernatant RNA sample volume was used for each qRT-PCR
reaction and each biological replicate loaded in duplicate; qRT-
PCR positive signals and presence of ()ss genomes were veriﬁed
using melting curve analysis. Reactions were run in glass
capillaries on the LightCycler 1.5 (Roche, Indianapolis, IN) using
the LightCycler software (Version 4). The following steps were
followed to carry out qRT-PCR: (1) RT: 10 min at 50 1C; (2) dena-
turing: 5 min at 95 1C; (3) ampliﬁcation: 10 s at 95 1C, 30 s at
60 1C, for 55 cycles; (4) melting curve: 1 min at 95 1C, 1 min at
55 1C, continuous [data collection] (0.1 1C/s) at 95 1C. qRT-PCR
primer binding sites varied by one base pair from the MARV-Mus
strain, however no bias for the assay was observed. Furthermore,
sequencing analysis of this MARV genomic region revealed
MARV-Ang to contain a higher number of mutations (Supple-
mentary Fig. S1B).Cloning of luciferase reporter constructs
The dual luciferase reporter system for these experiments was
constructed by modifying the MARV 3M–5M minigenome system
plasmid (Muhlberger et al., 1999). The Cypridina luciferase (CLuc)
gene was inserted adjacent to the encoded MARV leader region
and the Gaussian luciferase (GLuc) gene before the MARV trailer
sequence in the same orientation to that of the excised CAT gene.
To insert the various MARV-Mus and MARV-Ang regulatory
region (RR) sequences, site directed mutagenesis (QuickChange
Kit) was used to produce a BspEI restriction endonuclease (RE) site
at the 30-end of the CLuc gene and a BsaHI RE site the 50-end of the
GLuc gene. MARV RRs were inserted into these constructs by
cloning these MARV regions with primers speciﬁc to each MARV
strain’s RR, with primers at the 50-end of the MARV RR containing
an overlapping CLuc sequence and primers at the MARV RR 30-end
having an overlapping GLuc sequence. MARV-Mus and MARV-Ang
RRs correspond to genome nucleotides: NP-VP35 RR[2192–2944],
VP35-VP40 RR [3935–4567], VP40-GP RR [5480–5940], GP-VP30
RR [7987–8868], VP30-VP24 RR [9715–10206], and VP24-L RR
[10969–11480]. After each segment was ampliﬁed via RT-PCR,
each MARV RR was veriﬁed by sequencing, then MARV-Mus and
MARV-Ang RRs were cloned into the 3M–5M dual luciferase.
MARV-Mus genes NP, VP35 and L cloned into the pCAGGS vector,
along with the 3M–5M plasmid construct, were kindly provided
by Elke Muhlberger (Boston University); 3M–5M MARV-Mus NP/
VP35 and 3M–5M MARV-Ang NP/VP35 deletion mutants were
constructed as described above with PCR reactions designed to
amplify the NP/VP35 RRs with 200 bp deletion increments.
Luciferase reporter assays
Experiments with the dual luciferase reporter system were
conducted HeLa cells as previously described (Muhlberger et al.,
1998). Cells were transfected with equal amounts of in vitro
transcribed minigenome RNA (MEGAscript T7 Kit, Ambion) by
resuspending minigenome RNA and DOTAP reagent (Roche) in
25 mM HEPES, pH 7.5. 72 h post-RNA transfection, cellularsupernatants were removed and used to measure levels of GLuc
and CLuc protein signals using the BioLux Cypridina and Gaussia
Assay Kits (NEB, Ipswich, MA) according to the manufacturer’s
recommendations. Luciferase reporter assays with MARV-Mus
were conducted by infecting HeLa cells at MOI 0.1 then transfect-
ing minigenome RNA as described above; reporter gene levels
were measured 48–72 h post-transfection. Transient expression
of recombinant rZAP was achieved using the vector pCDNA4-TO-
myc-rZAP (AddGene plasmid number 17381) deposited by
Stephen Goff.Materials and methods
Viruses and cultured cells
Vero, Vero E6, HeLa, and Huh-7 cells were cultured in Delbec-
co’s Modiﬁed Eagle’s Medium (DMEM) supplemented with 10%
fetal calf serum (DMEM-10). Filoviruses Zaire strain Mayinga
Ebolavirus (EBOVZ, GenBank Accession number: AY142960);
Musoke Marburgvirus (MARV-Mus, GenBank Accession number:
DQ217792); and Angola Marburgvirus (MARV-Ang,GenBank
Accession number: DQ447658) were propagated in Vero cells
and supernatants subjugated to sucrose cushion puriﬁcation to
produce each respective virus stock. Brieﬂy, after Vero cells were
infected, supernatants were collected upon noticeable cytopathic
effect: 5 days for EBOVZ and 7 days for MARV-Mus and MARV-
Ang. Supernatants were pooled and centrifuged at 3000 g to
remove cellular debris. The supernatant was then transferred to
centrifuge tubes and underlaid with 20% sucrose in TNE buffer
(10 mM Tris-Cl, pH 7.4; 150 mM NaCl; 2 mM EDTA) and centri-
fuged at 25,000 g, for 2 h at 4 1C. Supernatant and the 20%
sucrose-TNE solutions were decanted, viral pellets resuspended in
TNE and pooled; then, pooled virus underwent sonication to
disperse viral aggregates and aliquots stored at 80 1C. After
2 days of storage, virus stock titers were completed by 50% tissue
culture infective dose (TCID50) and plaque assays with Vero E6
cells, viral genome quantiﬁcation of stock viruses was performed
by qRT-PCR and viral infection rates conﬁrmed via immunoﬂuor-
escence analysis. TCID50, plaque assay and qRT-PCR data showed
the relative differences in viral titers; with plaque assays data
used to adjust stocks to equal numbers of infectious viral
particles. All work with the infectious viruses was performed in
the CDC-certiﬁed biosafety level 4 (BSL-4) laboratory at the Texas
Biomedical Research Institute.
Immunoﬂuorescence analysis
Huh-7 and Vero E6 cells grown on coverslips were incubated
with the indicated amounts of ZEBOV, MARV-Mus, and MARV-Ang
at 37 1C for 1 h and washed twice with phosphate-buffered saline
(PBS). Thereafter, cells were grown to the stated time point post-
infection in DMEM-10. Cellular samples were washed twice with
PBS at the indicated time point and ﬁxed with 4% paraformaldehyde
for at least 12 h to inactivate viruses. Immunoﬂuorescent analysis
was performed by permeabilizing cells with 0.1% Triton in PBS for
5 min at room temperature. Samples were then washed with PBS
and treated with 0.1% glycine in PBS for 5 min and washed three
times with PBS. Coverslips were blocked with DMEM-10 for 1 h at
room temperature. To detect MARV proteins, rabbit anti-MARV
nucleoprotein complex (NC) (1:100) and monkey anti-MARV NP
(1:50) antibodies were added for 1 h at room temperature in
blocking buffer. Coverslips were washed 3 (3 min for each wash)
with PBS and primary antibodies detected by incubating each
sample at room temperature for 1 h in DMEM-10 with goat anti-
rabbit Alexa Flourophore 488 (Invitrogen, Carlsbad, CA) at 1:400
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Santa Cruz, CA) at1:200 dilution. Samples were washed 5 (3 min
each) and mounted onto slides using Prolong Gold antifade solution
with DAPI (Invitrogen) as recommended by the manufacturer (3).
Western blot analysis
Huh-7 and Vero E6 (4105) cells grown in 6-well plates were
incubated with the stated MOI of ZEBOV, MARV-Mus and MARV-
Ang. At each indicated time point, cellular supernatant was
removed, cells were washed brieﬂy with PBS, and directly lysed
in each well with 250 ml of 2 lysis buffer (114 mM Tris–HCl,
pH 6.8; 2.5% SDS; 125 mM dithiothreitol; 25% glycerol; 0.25%
bromphenol blue). Cell lysates were transferred to fresh tubes and
boiled at 100 1C for 10 min to inactivate virus, protein lysates
were quantiﬁed using the EZQ protein quantiﬁcation kit (Invitro-
gen) and equal amounts of protein were loaded onto 10% gels for
SDS-PAGE. After SDS-PAGE, protein was transferred to PVDF
membranes (Millipore, Billerica, MA) via semi-dry blot transfer,
then membranes were blocked with 5% milk in PBS containing
01.% Tween-20 for 1 h at room temperature, followed by an
overnight incubation at 4 1C in a solution containing 5% bovine
serum albumin (BSA), fraction V (Sigma, St. Louis, MO) in PBS
with one of the following: goat anti-EBOVZ antigen (1:5000)
rabbit anti-EBOV VP30 (1:5000), guinea pig anti-EBOV GP
(1:2000), rabbit anti-MARV GP (1:20,000), guinea pig anti-MARV
VP30 (1:10,000) or guinea pig anti-MARV VP35 (1:15,000), all
kindly provided by Elke Muehlberger, Boston University School of
Medicine. MARV NP was detected using llama anti-MARV NP AP-
conjugated antibody (1:2000) provided by Andrew Hayhurst,
Texas Biomedical Research Institute. Following overnight incuba-
tion, membranes were washed 4 (5 min each) in PBS-0.1%
Tween-20 and incubated at room temperature in 5% milk in PBS
containing one of the following corresponding antibodies: goat
anti-rabbit horseradish peroxidase- (HRP) conjugated antibody
(1:50,000, Promega, Madison, WI), goat anti-guinea pig-HRP
(1:50,000, Sigma) or rabbit anti-goat-HRP (1:50,000, Sigma).
Protein bands were then visualized by exposing membranes to
SuperSignal West Femto or SuperSignal West Pico Chemilumi-
nescent substrates (Pierce, Rockford, IL) according to the manu-
facturer’s instructions and developed using CL-XPosure ﬁlm
(Pierce). Filovirus proteins were visualized sequentially by strip-
ping probed PVDF membranes utilizing the Restore Western Blot
Stripping Buffer (Pierce), then incubating with a different anti-
ﬁlovirus protein antibody. For all membranes rabbit anti-Beta
Actin (1:5000, Sigma) was used as a loading control. MARV NP
protein bands were visualized using Western Blue Stabilized
Substrate for AP (Promega). Protein band intensities were calcu-
lated using Quantity One 1-D Analysis software (Bio-Rad,
Hercules, CA) from three experimental replicates.
RNA isolation
Huh-7 and Vero E6 cells were infected with ZEBOV, MARV-
Mus, and MARV-Ang at either 5 or 0.01 MOI and incubated in
DMEM-10 for indicated time points. Total cellular RNA was
isolated with RNA-Bee solution (Tel-Test, Inc., Friendswood, TX)
according to the manufacturer’s recommendation and resus-
pended in 35 ml of Nuclease-Free DEPC water. Poly (A) RNA was
isolated from total cellular RNA with the Poly(A)Purist RNA Kit
(Ambion), with puriﬁed poly(A) RNA eluted in 200 ml of the RNA
solution. RNA in cellular supernatants was isolated from 125 ml of
supernatant combined in a ratio of 1:4 with RNA-STAT 50 LS
(Tel-Test, Inc.). RNA was extracted according to the manufacturer’s
recommendations and resuspended in 15 ml of Nuclease-Free DEPC
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